IMBDx Expands CancerFind Screening to 12 Types of Cancer

IMBDx, a liquid biopsy-based multi-cancer early detection (MCED) technology company, announced on December 5 that its AI-powered early cancer screening test, CancerFind, can now detect a total of 12 types of solid tumors. This announcement was made at the European Society for Medical Oncology (ESMO) Asia Congress.

By adding four more cancers-renal cancer, bladder cancer, cervical cancer, and endometrial cancer-to the existing eight types, the company has expanded its coverage to include over 70% of all cancer patients in Korea.

Two years ago, IMBDx disclosed the early cancer screening performance of CancerFind for eight major cancers: colorectal, gastric, liver, pancreatic, lung, breast, ovarian, and prostate cancers. At the time, CEO Kim Taeyou stated, "We aim to provide a comprehensive screening tool by expanding to cancers for which no standard screening tests exist."

CancerFind now offers early detection opportunities for a total of 12 solid tumors. As of 2022, this covers approximately 78% of Korea's cancer patient population, excluding thyroid cancer, which is about 280,000 people. The medical community considers this a significant technological advancement that could bring meaningful changes to the entire early cancer screening system in Korea.

CancerFind maximizes accuracy by applying an ensemble AI model that integrates four biomarkers: methylation patterns of cell-free DNA (cfDNA) in blood, copy number variation (CNV), and fragment size. Clinical validation across 12 cancer types showed a sensitivity of 91.8% and a specificity of 97.3%. Even for cancers that are difficult to detect early, the tool demonstrated high sensitivity-86.9% for stage 1 and 88.6% for stage 2-proving its effectiveness as an early cancer screening tool.

Kim Taeyou, CEO of IMBDx, commented, "Early detection of cancer is the most critical factor in determining survival rates. Expanding the range and enhancing the performance of our test is a meaningful step toward our goal of improving public health."

He added, "Through technological innovation, we will reduce the cost burden and increase accessibility by achieving the same performance with less data. We are committed to establishing CancerFind as a universal early cancer screening platform, including cancers for which no standard screening tests exist."

Starting with its presentation at ESMO Asia 2025, IMBDx plans to actively promote CancerFind's technological competitiveness and accelerate its entry into the global market.